Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ty, A. U.
Right arrow Articles by Wong, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ty, A. U.
Right arrow Articles by Wong, M. C.
Related Collections
Right arrow All Oncology
Right arrow Primary brain tumor
Right arrow Chemotherapy-tumor
Right arrow Cerebral venous thrombosis
Right arrow Clinical trials Observational study (Cohort, Case control)
NEUROLOGY 2006;66:247-249
© 2006 American Academy of Neurology
Brief Communications

Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: A Singapore experience

A. U. Ty, MD, S. J. See, MD, J. P. Rao, MD, J.B.K. Khoo, MD, FRCR and M. C. Wong, FRCP

From the Department of Neurology (A.U.T., S.J.S., M.C.W.), National Neuroscience Institute (Singapore General Hospital campus); Department of Neurosurgery (J.P.R.), National Neuroscience Institute (Tan Tock Seng Hospital campus); and Division of Oncologic Imaging (J.B.K.K.) and Brain Tumor Research Laboratory, Division of Medical Sciences (M.C.W.), National Cancer Center, Singapore.

Address correspondence and reprint requests to Prof. Meng Cheong Wong, National Neuroscience Institute (Singapore General Hospital campus), Block 6, Level 8, Outram Road, Singapore 169608; e-mail: gnewmc{at}sgh.com.sg.

The authors propose "decreased-dose-intensity" PCV (procarbazine, lomustine [CCNU], and vincristine) chemotherapy for Asian patients with oligodendroglial tumors. In this study, all seven patients with oligodendroglioma (OD) and eight with anaplastic oligodendroglioma (AO) had objective responses or stable disease. Median progression-free survival was greater than 29 months (OD) and 36.5 months or greater (AO); 86% of patients with OD and 63% with AO remain progression-free. Twenty-four Common Toxicity Criteria Grade 3/4 adverse events were noted.

Disclosure: The authors report no conflicts of interest.

Received December 21, 2004. Accepted in final form October 10, 2005.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.